TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant ...

“Most vaccines are based on attenuated or inactivated viruses, but our next-generation strategy enables us to prioritize not just safety and efficacy but also plasticity in the formulation so that the ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

Ukrainian President Volodymyr Zelenskyy will personally attend the World Economic Forum in Davos, held from January 20-24. US ...

Studies conducted in mice have shown that the COVID-19 vaccine being developed by researchers at the University of São Paulo's Medical School (FM-USP) in Brazil is safe and efficacious.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

A central focus of the discussions was the formulation of a comprehensive roadmap for practical cooperation across a wide ...

BOSTON, MA / ACCESSWIRE / / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it has ...